Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy.
Microb Pathog
; 55: 9-15, 2013 Feb.
Article
en En
| MEDLINE
| ID: mdl-23247146
ABSTRACT
Respiratory viral infections in infants and young children frequently cause illness that can easily progress to hospitalization and death. There are currently no licensed vaccines to prevent respiratory viral disease in children younger than 6 months, reflecting safety concerns and the difficulty in inducing effective immune responses in infants. This review discusses vaccines that have been developed, or are currently being developed, against influenza and respiratory syncytial virus, with a focus on studies performed to demonstrate their safety and efficacy, and the impact of immunologic immaturity and maternal antibodies on the infant response to vaccines.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Orthomyxoviridae
/
Vacunas contra la Influenza
/
Virus Sincitial Respiratorio Humano
/
Infecciones por Virus Sincitial Respiratorio
/
Vacunas contra Virus Sincitial Respiratorio
/
Gripe Humana
Límite:
Animals
/
Humans
/
Infant
Idioma:
En
Año:
2013
Tipo del documento:
Article